📣 Calling all causal inference users!
👋 Hello #IDTwitter, #EpiTwitter, #CausalInfer, I am conducting a survey as part of my PhD studies and I need your help! 🎓🔬
🌐📝 Please take a few moments to complete the survey by clicking on the following link:
https://t.co/4F03VOAFjQ
Higher rates of cefiderocol resistance among NDM producing Klebsiella bloodstream isolates applying EUCAST over CLSI breakpoints - wish there could be some better agreement on this ! @burcucella https://t.co/0rpEULtkNY
Collectively, 1000s of hours of work. Very proud to present to you all the second @Wiki_Guidelines for the diagnosis and management of infective endocarditis.
@DrToddLee@BradSpellberg@JonathanRyderMD @syctong and many many many others
Thank you
Does competition make us less moral? New research says yes, but only a little bit
https://t.co/mYfazvX3yV
Great team effort. Special thanks to the #ManyDesigns coordinators:
@chrhuber_, Anna Dreber, Jürgen Huber, Magnus Johannesson, Michael Kirchler, @UtzWeitzel & @flxhlzmstr
@BJegorovic@DrNeilStone Like Neil said. We offer treatment for latent TB if it is positive. Ppl from endemic countries and those who will undergo immunosuppressive tx get screened and treated. Latent TB comprises ~10% of the ID outpatients (Australian setting).
From the micro working group of @snap_trial@DrToddLee@Josh_S_Davis @syctong
🆕️⚡️#JAC Multi-site, international laboratory study to assess the performance of penicillin susceptibility testing of Staphylococcus aureus #IDTwitter https://t.co/baUv1OpDLQ
From the micro working group of @snap_trial@DrToddLee@Josh_S_Davis @syctong
🆕️⚡️#JAC Multi-site, international laboratory study to assess the performance of penicillin susceptibility testing of Staphylococcus aureus #IDTwitter https://t.co/baUv1OpDLQ
More isolates with ⬆️ voriconzaole MIC values in 2020-21. No difference in azole resistance between North QLD vs Southeast QLD acquisition 🇦🇺@burcucella@peter_simos
🔈 CEFAZOLIN, CEFTRIAXONE, and CEFEPIME are all reasonable to use in the VAST MAJORITY of penicillin allergy patients* INCLUDING anaphylaxis 🔈
*exception: severe cutaneous adverse reactions (i.e. SJS, TEN, etc.)